Xilio Therapeutics, Inc.

Historical 13F Holders

Symbol
XLO
CUSIP
98422T100
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 98422T100 since 12/18/2024, largest first.

Filer % of Class Filed
Gilead Sciences, Inc. 13G/A 19.9% 2/12/2026
Event 12/31/2025
Coastlands Capital LP 13G
10.0% 12/11/2025
Event 12/4/2025
Sirenia Capital Management LP 13G
9.9% 5/15/2026
Event 3/31/2026
AbbVie Inc. 13G 9.0% 2/18/2025
Event 2/11/2025
Bain Capital Life Sciences Fund II, L.P. 13G/A
8.5% 2/17/2026
Event 12/31/2025
StemPoint Capital LP 13G/A
8.4% 2/17/2026
Event 12/31/2025
Frazier Life Sciences Public Fund, L.P. 13G/A
6.7% 2/13/2026
Event 12/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
Point72 Asset Management, L.P. 13G/A
0% 5/15/2026
Event 3/31/2026
Rock Springs Capital Management LP 13G/A
0% 5/15/2025
Event 3/31/2025

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 1 650 k $5.89M
2026 Q2 1 650 k $6.23M
2026 Q1 1 650 k $5.47M
2025 Q4 37 39.7 M $25.4M
2025 Q3 36 22.1 M $18.6M
2025 Q2 36 23.8 M $16.2M
2025 Q1 36 22.5 M $16.3M
2024 Q4 36 25.9 M $24.7M
2024 Q3 34 16.0 M $12.6M
2024 Q2 33 14.5 M $13.7M
2024 Q1 32 12.5 M $13.5M
2023 Q4 35 16.4 M $9.03M
2023 Q3 32 15.9 M $33.5M
2023 Q2 33 16.0 M $41.9M
2023 Q1 33 16.1 M $51.0M
2022 Q4 29 15.9 M $42.8M
2022 Q3 30 16.6 M $48.3M
2022 Q2 34 17.9 M $52.2M
2022 Q1 42 18.8 M $133M
2021 Q4 43 19.0 M $303M